Orgenesis Inc. (ORGS)
USD 2.4
(10.6%)
USD 2.4
(10.6%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 14.55 Million USD | -84.0% |
| 2022 | 90.92 Million USD | 51.95% |
| 2021 | 59.84 Million USD | -22.97% |
| 2020 | 77.68 Million USD | -16.01% |
| 2019 | 92.49 Million USD | 22.6% |
| 2018 | 75.44 Million USD | 89.22% |
| 2017 | 39.87 Million USD | 19.07% |
| 2016 | 33.48 Million USD | -13.58% |
| 2015 | 38.74 Million USD | 1622.94% |
| 2014 | 2.24 Million USD | 1868.95% |
| 2013 | 114.22 Thousand USD | 137.14% |
| 2012 | 48.16 Thousand USD | 1958.42% |
| 2011 | 2340.00 USD | 44.71% |
| 2010 | 1617.00 USD | -94.92% |
| 2009 | 31.85 Thousand USD | -42.09% |
| 2008 | 55 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 30.57 Million USD | -1.11% |
| 2024 Q1 | 30.92 Million USD | 112.48% |
| 2023 Q1 | 93.26 Million USD | 2.57% |
| 2023 FY | 14.55 Million USD | -84.0% |
| 2023 Q2 | 54.76 Million USD | -41.28% |
| 2023 Q3 | 45.29 Million USD | -17.29% |
| 2023 Q4 | 14.55 Million USD | -67.88% |
| 2022 Q4 | 90.92 Million USD | 28.63% |
| 2022 Q3 | 70.69 Million USD | 12.57% |
| 2022 Q1 | 58.53 Million USD | -2.18% |
| 2022 FY | 90.92 Million USD | 51.95% |
| 2022 Q2 | 62.79 Million USD | 7.28% |
| 2021 Q3 | 65.2 Million USD | -13.7% |
| 2021 Q4 | 59.84 Million USD | -8.22% |
| 2021 Q2 | 75.55 Million USD | -7.98% |
| 2021 FY | 59.84 Million USD | -22.97% |
| 2021 Q1 | 82.11 Million USD | 5.7% |
| 2020 Q2 | 119.19 Million USD | -6.3% |
| 2020 FY | 77.68 Million USD | -16.01% |
| 2020 Q1 | 127.2 Million USD | 37.53% |
| 2020 Q3 | 110.75 Million USD | -7.08% |
| 2020 Q4 | 77.68 Million USD | -29.86% |
| 2019 Q1 | 84.77 Million USD | 12.36% |
| 2019 Q2 | 84.55 Million USD | -0.25% |
| 2019 Q4 | 92.49 Million USD | 16.2% |
| 2019 FY | 92.49 Million USD | 22.6% |
| 2019 Q3 | 79.59 Million USD | -5.86% |
| 2018 Q3 | 69.29 Million USD | 47.33% |
| 2018 FY | 75.44 Million USD | 89.22% |
| 2018 Q4 | 75.44 Million USD | 8.88% |
| 2018 Q2 | 47.03 Million USD | 10.9% |
| 2018 Q1 | 42.41 Million USD | 6.37% |
| 2017 FY | 39.87 Million USD | 19.07% |
| 2017 Q2 | 36.26 Million USD | -0.01% |
| 2017 Q1 | 36.27 Million USD | 8.32% |
| 2017 Q4 | 39.87 Million USD | 6.55% |
| 2017 Q3 | 37.42 Million USD | 3.18% |
| 2016 FY | 33.48 Million USD | -13.58% |
| 2016 Q4 | 33.48 Million USD | -8.39% |
| 2016 Q1 | 36.2 Million USD | -6.58% |
| 2016 Q2 | 36.74 Million USD | 1.51% |
| 2016 Q3 | 36.55 Million USD | -0.52% |
| 2015 FY | 38.74 Million USD | 1622.94% |
| 2015 Q2 | 34.58 Million USD | 2719.54% |
| 2015 Q1 | 1.22 Million USD | -45.46% |
| 2015 Q3 | 35.55 Million USD | 2.8% |
| 2015 Q4 | 38.74 Million USD | 8.99% |
| 2014 Q1 | 293.36 Thousand USD | 156.84% |
| 2014 Q4 | 2.24 Million USD | 35.47% |
| 2014 Q2 | 154.33 Thousand USD | -47.39% |
| 2014 FY | 2.24 Million USD | 1868.95% |
| 2014 Q3 | 1.66 Million USD | 975.66% |
| 2013 Q1 | 97.83 Thousand USD | 103.11% |
| 2013 FY | 114.22 Thousand USD | 137.14% |
| 2013 Q4 | 114.22 Thousand USD | -80.95% |
| 2013 Q3 | 599.62 Thousand USD | -47.09% |
| 2013 Q2 | 1.13 Million USD | 1058.37% |
| 2012 Q2 | 181.54 Thousand USD | -48.69% |
| 2012 FY | 48.16 Thousand USD | 1958.42% |
| 2012 Q4 | 48.16 Thousand USD | -86.23% |
| 2012 Q3 | 349.86 Thousand USD | 92.71% |
| 2012 Q1 | 353.79 Thousand USD | 15019.4% |
| 2011 FY | 2340.00 USD | 44.71% |
| 2011 Q1 | 7210.00 USD | 345.89% |
| 2011 Q2 | 6015.00 USD | -16.57% |
| 2011 Q3 | 5125.00 USD | -14.8% |
| 2011 Q4 | 2340.00 USD | -54.34% |
| 2010 Q2 | 22.68 Thousand USD | -15.97% |
| 2010 Q1 | 26.99 Thousand USD | -15.25% |
| 2010 FY | 1617.00 USD | -94.92% |
| 2010 Q3 | 19.72 Thousand USD | -13.06% |
| 2010 Q4 | 1617.00 USD | -91.8% |
| 2009 Q4 | 31.85 Thousand USD | -5.39% |
| 2009 Q3 | 33.66 Thousand USD | 0.0% |
| 2009 FY | 31.85 Thousand USD | -42.09% |
| 2008 FY | 55 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -4764.791% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -153.696% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 0.973% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 53.381% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -351.925% |
| Better Therapeutics, Inc. | 22.94 Million USD | 36.573% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 49.254% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -290.436% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 29.167% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 31.108% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 77.418% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -518.258% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 79.503% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 44.333% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -19049.132% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -19.583% |
| Molecular Templates, Inc. | 35.38 Million USD | 58.873% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -232.875% |
| NexImmune, Inc. | 8.59 Million USD | -69.328% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -23.301% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -11574.944% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -156.179% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -3609.737% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 96.922% |
| Statera Biopharma, Inc. | 21.16 Million USD | 31.26% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -44.008% |
| Trevena, Inc. | 40.6 Million USD | 64.162% |
| Vaxxinity, Inc. | 44.35 Million USD | 67.19% |
| Vaccinex, Inc. | 3.63 Million USD | -300.771% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -36595.582% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 74.331% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -2518.608% |